Abstract
The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, and substituted oxazolone compounds targeting IKZF1-4 transcription factors. These compounds demonstrate exceptional efficacy in degrading pathogenic proteins, reprogramming immune responses, and facilitating tumor immunity. This dual approach underscores the potential of cellular degradation systems in precision medicine.